drugset / Trial / NCT01005121

Colchicine for Diabetic Nephropathy

NCT01005121

Phase 2 Unknown 12 enrolled Prof.Avi Livneh
NaSingle-groupOpen-labelTreatment

Summary

Patients with diabetic nephropathy and proteinuria, despite maximal anti- hypertensive and anti-glucose treatment, will receive colchicine for six months, 2 mg a day, during which their 24 hour urine protein and renal function tests will be monitored. The investigators' hypothesis is that colchicine will diminish proteinuria and might also help slow down the development of end stage renal failure in the long run.

Timeline

Start
2009-12
Primary completion
2014-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Colchicine Small molecule 2 mg Oral